The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical ...(et lossfor the six months ended June 30 ...)

The decrease in loss from continuing operations for the second quarter ended June 30, 2008 primarily reflects savings in operations for legal expenses and costs associated with the continued investment in Quigley Pharma, a wholly owned Ethical Pharmaceutical subsidiary developing natural-source potential prescription and other products. The overall slight increase in loss from continuing operations for the six months ended June 30, 2008 primarily reflects the reduction of gross profit from reduced sales as compared to 2007.

The Quigley Corporation continues to enhance its position to capitalize on the growth potential of Quigley Pharma by investing in key pharmaceutical research and development including QR-333, an investigational new drug for treating conditions associated with diabetic peripheral neuropathy. The Company is in the midst of Phase II (b) clinical study for QR-333, which is a key segment of the Company's strategic initiatives to generate future growth.

Over 170 million people have diabetes worldwide including an estimated 20 million people within the United States, comprising approximately 7% of the country's population. Nearly 60% of people with diabetes will suffer mild to severe nerve damage due to diabetic peripheral neuropathy, the treatment of which may offer a significant opportunity for QR-333. In addition to QR-333, The Company continues to invest in developing natural-source potential products for disease states associated with inflammation, the protection against infectious diseases in poultry products as well as protection against ionizing radiation.

No tax provision or benefits, to reduce losses, are provided for the quarter and six month period ended June 30, 2008 and 2007, since the Company is in a net operating loss carry-forward position for which a valuation has be
'/>"/>